Table 1.
Study | CN | MCI | Dementia | Median follow-up (years) | Gender (% of male) | Age | APOE E4 carriers | CSF Abeta/Tau available |
---|---|---|---|---|---|---|---|---|
ADNI1 | 229 | 397 | 193 | 2.2 (1.7–3.1) | 58.2% | 75 (71–80) | 48.8% | 415 |
ADNI2/ GO | 297 | 452 | 150 | 2.1 (1.1–4.0) | 53.3% | 74 (68–79) | 43.6% | 779 |
BLSA | 1094 | 11 | 9 | 4.0 (0.0–6.0) | 47% | 67 (58–76) | 25% | 0 |
For age and length of follow-ups, median value with first and third quartile are reported. APOE E4 carriers include heterozygotes and homozygotes.